TRVI

$13.87+0.11 (+0.80%)

Pre-Market$13.90+0.03 (+0.22%)· Last close May 1

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.

Overview Intraday ResearchPRO BacktestPRO Ask AIPRO TranscriptsPRO StatementsPRO

Intraday

Custom Range:

No data available for this range. Intraday data may be limited by the exchange.

Loading stock data…